Toxic aldehyde related diseases and treatment
The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
1. A method of treating uveitis, comprising:
administering to a subject with uveitis a therapeutically effective amount of a compound of formula (I):
or a pharmaceutically acceptable salt thereof, wherein,
X is CH; Z is N; and Y is C with the —NH 2 attached;
p is 0, 1, 2, or 3;
each R B is independently a halogen, hydroxyl, carbamoyl, amino, or aryl;
R A is
and
each Q a is independently a C 1 -C 6 straight chain alkyl.
2. The method of claim 1 , wherein p is 1.
3. The method of claim 1 , wherein each Q a is methyl.
4. The method of claim 1 , wherein R B is a halogen.
5. The method of claim 4 , wherein the halogen is chlorine or fluorine.
6. The method of claim 5 , wherein the halogen is chlorine.
7. The method of claim 1 , wherein the compound is present at a concentration from about 0.05 to about 10% w/v.
8. The method of claim 1 , wherein the compound is present at a concentration from about 0.1 to about 5% w/v.
9. The method of claim 1 , wherein the compound is present at a concentration from about 0.1 to about 2% w/v.
10. The method of claim 1 , wherein the compound is present at a concentration from about 0.05 to about 1.5% w/v.
11. The method of claim 1 , wherein the compound is present at a concentration from about 0.09 to about 0.5% w/v.
12. The method of claim 1 , wherein the compound present in an admixture with a cyclodextrin.
13. The method of claim 12 , wherein the cyclodextrin comprises β-cyclodextrin or a pharmaceutically acceptable salt thereof.
14. The method of claim 13 , wherein the β-cyclodextrin is selected from the group consisting of sulfobutylether-β-cyclodextrin, 2-hydroxypropyl-β-cyclodextrin, and 3-hydroxypropyl-β-cyclodextrin.
15. The method of claim 14 , wherein the β-cyclodextrin is sulfobutylether-β-cyclodextrin or a pharmaceutically acceptable salt thereof.
16. The method of claim 15 , wherein the salt of sulfobutylether-β-cyclodextrin is sulfobutylether-β-cyclodextrin sodium salt.
17. The method of claim 16 , wherein the sulfobutylether-β-cyclodextrin sodium salt is present at about 0.01 to about 30% w/v.
18. The method of claim 17 , wherein the sulfobutylether-β-cyclodextrin is present at about 2 to about 25% w/v.
19. The method of claim 18 , wherein the sulfobutylether-β-cyclodextrin is present at about 6 to about 20% w/v.
20. The method of claim 1 , wherein for the compound of formula (I):
R A is
R B is halogen; and
p is 1.
21. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
22. The method of claim 1 , wherein the compound is administered topically to an eye of the subject with uveitis.
23. The method of claim 22 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
24. The method of claim 23 , wherein the compound is administered topically as an aqueous composition comprising the compound, and a cyclodextrin or a pharmaceutically acceptable salt thereof.
25. The method of claim 24 , wherein the cyclodextrin is β-cyclodextrin or a pharmaceutically acceptable salt thereof.
26. The method of claim 25 , wherein the β-cyclodextrin is sulfobutylether-β-cyclodextrin, hydroxypropyl-β-cyclodextrin, or a pharmaceutically acceptable salt thereof.
27. The method of claim 26 , wherein the β-cyclodextrin is hydroxypropyl-β-cyclodextrin, or a pharmaceutically acceptable salt thereof.
28. The method of claim 27 , wherein the hydroxypropyl-β-cyclodextrin is 2-hydroxypropyl-β-cyclodextrin, 3-hydroxypropyl-β-cyclodextrin, or a pharmaceutically acceptable salt thereof.
29. The method of claim 26 , wherein the β-cyclodextrin is sulfobutylether-β-cyclodextrin, or a pharmaceutically acceptable salt thereof.
30. The method of claim 29 , wherein the sulfobutylether-β-cyclodextrin is present at about 0.01% to about 30% w/v.
31. The method of claim 30 , wherein the sulfobutylether-β-cyclodextrin is present at about 5% to about 25% w/v.
32. The method of claim 31 , wherein the compound is present from 0.09 to 0.5% w/v.
33. The method of claim 31 , wherein the compound is present from 0.08 to 1% w/v.
34. The method of claim 31 , wherein the compound is present at a concentration from 0.06 to 5% w/v.
35. The method of claim 31 , wherein the compound is present at a concentration from about 0.1 to about 5% w/v.
36. The method of claim 31 , wherein the compound is present at a concentration from about 0.2 to about 2.0% w/v.
37. The method of claim 31 , wherein the compound is present at a concentration of about 0.5% w/v.
38. The method of claim 24 , wherein the compound is present at about 0 .08% to 1.0% w/v; and the cyclodextrin is sulfobutylether-β-cyclodextrin, wherein the sulfobutylether- 62 -cyclodextrin is present at about 6%-12% w/v.
39. The method of claim 38 , wherein the compound is present at about 0.09% to 0.5% w/v.
40. The method of claim 39 , wherein the sulfobutylether-β-cyclodextrin is present at about 9.5% w/v.